American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026
Think PEN-FAST: Evaluation of implementing PEN-FAST into pharmacist-led medication reconciliation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Linville Samantha, Metzger Alex, Etemady-Deylamy Ali, Patri Manokiran, Rondeau Hunter
Аннотация
PURPOSE: Approximately 10% of US patients report a penicillin allergy, yet fewer than 1% have a true immunoglobulin E-mediated reaction. Mislabeled allergies contribute to unnecessary use of broad-spectrum antibiotics, increasing healthcare costs, hospital stays, antimicrobial resistance, and mortality. Despite guideline recommendations for risk stratification and allergy delabeling, implementation remains limited. PEN-FAST is a validated clinical tool used to facilitate delabeling without resource-intensive skin testing. This study aimed to determine the prevalence of low-risk penicillin allergy among adult patients using the PEN-FAST tool within a pharmacist-led medication reconciliation process.
METHODS: A multicenter, retrospective prevalence study was conducted at 2 community hospitals. Patients admitted or seen in the emergency department from September 16 through December 16, 2024, with a documented penicillin allergy who underwent a pharmacist-performed PEN-FAST assessment were included. The primary outcome was the proportion of patients classified as having low-risk penicillin allergy (PEN-FAST score of <3). Secondary outcomes included allergy delabeling rates and the frequency of direct oral penicillin challenges. Descriptive analysis was used to evaluate the results.
RESULTS: Of 95 patients assessed, 74% (n = 70) were classified as low risk. Among these low-risk patients, 10% (n = 7) had their allergy label removed and 3% (n = 2) underwent a direct oral penicillin challenge, with both tolerating penicillin without adverse reactions.
CONCLUSION: These findings suggest that pharmacist-led PEN-FAST implementation is a feasible strategy to identify low-risk penicillin allergies, but allergy delabeling and oral challenge rates remain low. Further efforts are needed to integrate PEN-FAST into clinical workflows and enhance antimicrobial stewardship.
METHODS: A multicenter, retrospective prevalence study was conducted at 2 community hospitals. Patients admitted or seen in the emergency department from September 16 through December 16, 2024, with a documented penicillin allergy who underwent a pharmacist-performed PEN-FAST assessment were included. The primary outcome was the proportion of patients classified as having low-risk penicillin allergy (PEN-FAST score of <3). Secondary outcomes included allergy delabeling rates and the frequency of direct oral penicillin challenges. Descriptive analysis was used to evaluate the results.
RESULTS: Of 95 patients assessed, 74% (n = 70) were classified as low risk. Among these low-risk patients, 10% (n = 7) had their allergy label removed and 3% (n = 2) underwent a direct oral penicillin challenge, with both tolerating penicillin without adverse reactions.
CONCLUSION: These findings suggest that pharmacist-led PEN-FAST implementation is a feasible strategy to identify low-risk penicillin allergies, but allergy delabeling and oral challenge rates remain low. Further efforts are needed to integrate PEN-FAST into clinical workflows and enhance antimicrobial stewardship.